Omeros Co. (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Analysts

Omeros Co. (NASDAQ:OMER - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $22.50.

OMER has been the subject of a number of research reports. Cantor Fitzgerald restated a "neutral" rating on shares of Omeros in a research note on Thursday, November 14th. D. Boral Capital reissued a "buy" rating and set a $36.00 price objective on shares of Omeros in a research report on Thursday. RODMAN&RENSHAW raised Omeros to a "strong-buy" rating in a report on Thursday, November 14th. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Friday. Finally, StockNews.com upgraded Omeros from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th.

Institutional Investors Weigh In On Omeros

Hedge funds have recently modified their holdings of the company. MML Investors Services LLC boosted its holdings in Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 3,000 shares during the last quarter. State Street Corp raised its stake in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock worth $4,867,000 after buying an additional 3,839 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Omeros by 7.2% in the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company's stock valued at $235,000 after buying an additional 4,000 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Omeros by 21.2% during the fourth quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company's stock valued at $241,000 after buying an additional 4,257 shares during the period. Finally, Rhumbline Advisers increased its holdings in shares of Omeros by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company's stock worth $454,000 after buying an additional 6,435 shares during the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Price Performance

Shares of Omeros stock traded up $0.15 on Friday, hitting $9.33. 522,245 shares of the company's stock traded hands, compared to its average volume of 664,031. The firm's 50-day moving average price is $9.25 and its two-hundred day moving average price is $5.96. The stock has a market capitalization of $540.67 million, a PE ratio of -4.04 and a beta of 2.01. Omeros has a one year low of $2.61 and a one year high of $13.60.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.